Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0DNUKS
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
wO2023232144A1ADC-5
|
|||||
| Synonyms |
WO2023232144A1ADC-5
Click to Show/Hide
|
|||||
| Organization |
GeneQuantum Healthcare (Suzhou) Co. Ltd.
|
|||||
| Drug Status |
Investigative
|
|||||
| Drug-to-Antibody Ratio |
1.87
|
|||||
| Structure |
|
|||||
| Antibody Name |
anti-TROP2 antibody mAb-2
|
Antibody Info | ||||
| Antigen Name |
Tumor-associated calcium signal transducer 2 (TACSTD2)
|
Antigen Info | ||||
| Payload Name |
Undisclosed
|
|||||
| Therapeutic Target |
Stimulator of interferon genes protein (STING1)
|
Target Info | ||||
| Linker Name |
Undisclosed
|
|||||
| Conjugate Type |
Site asparaginate random conjugation.
|
|||||
| Combination Type |
LP-2
|
|||||
General Information of The Activity Data Related to This ADC
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | 0.1017 nM | High TROP2 expression (TROP2 +++) | ||
| Method Description |
Cytotoxicity of ADC-2 to BxPC-3 cells
|
||||
| In Vitro Model | Pancreatic ductal adenocarcinoma | BxPC-3 cells | CVCL_0186 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | 0.1121 nM | High TROP2 expression (TROP2 +++) | ||
| Method Description |
Cytotoxicity of ADC to FaDu cells
|
||||
| In Vitro Model | Hypopharyngeal squamous cell carcinoma | FaDu cells | CVCL_1218 | ||
References